ASH 2023 – Stephan Stilgenbauer
Stephan Stilgenbauer discusses the current evidence regarding the treatment of Richter transformation with modern agents and reviews the findings of the RT1 trial presented at the ASH 2023 meeting. Finally, he highlights future combinations of novel agents like adding the next-generation BCL-2 inhibitor sonrotoclax to tislelizumab plus zanubrutinib which will be investigated in the amendment of the RT1 trial or the use of the non-covalent BTK inhibitor pirtobrutinib combined with epcoritamab, a bispecific antibody, that will be in the focus of the international RT2 trial.
Here is the full ASH 2023 report.
More posts
Exploring chemotherapy-free approaches in the treatment of DLBCL
Exploring chemotherapy-free approaches in the treatment of DLBCL Smart Stop: qu
Updated findings in CLL with a focus on BTK- and Bcl-2–targeted therapies
Updated findings in CLL with a focus on BTK- and Bcl-2–targeted therapies Treat
Follicular lymphoma: BTK inhibition and bispecific antibodies
Follicular lymphoma: BTK inhibition and bispecific antibodies Acalabrutinib in
Improving responses in multiple myeloma
Improving responses in multiple myeloma PERSEUS: D-VRd vs. VRd An established t
Waldenström macroglobulinemia: optimizing outcomes in the first and later lines
Waldenström macroglobulinemia: optimizing outcomes in the first and later lines
Mantle cell lymphoma: emerging treatment regimens and new standards
Mantle cell lymphoma: emerging treatment regimens and new standards SYMPATICO:
